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TABLE I. Change in protocol-defined asthma exacerbation rate
over the 24-week treatment period (mITT population), and by
high and low eosinophil counts at screening
mITT population
Omalizumab
(n 5 157)
Placebo
(n 5 171)
No. of protocol-defined asthma
exacerbations, n (%)
0 133 (84.7) 138 (80.7)
1 21 (13.4) 25 (14.6)
>_2 3 (1.9) 8 (4.7)
Unadjusted exacerbation rate* 0.21 0.26
Poisson regression
Ratio of exacerbation rates (95% CI) 0.73 (0.44-1.24)
P value .25
Eosinophil counts at screening
Omalizumab
(n 5 51)
Placebo
(n 5 40)
High
No. of protocol-defined asthma
exacerbations, n (%)
0 41 (80.4) 25 (62.5)
1 9 (17.6) 9 (22.5)
>_2 1 (2.0) 6 (15.0)
Unadjusted exacerbation rate* 0.25 0.59
Poisson regression§
Ratio of exacerbation rates (95% CI) 0.41 (0.20-0.82)
P value .0125
Low (n 5 56) (n 5 70)
No. of protocol-defined asthma
exacerbations, n (%)
0 48 (85.7) 60 (85.7)
1 7 (12.5) 9 (12.9)
>_2 1 (1.8) 1 (1.4)
Unadjusted exacerbation rate* 0.17 0.16
Poisson regression
Ratio of exacerbation rates§ (95% CI) 1.07 (0.45-2.53)
P value .8807
mITT, Modified intent-to-treat population.
*Number of protocol-defined asthma exacerbations/total patient-treatment period.
Poisson regression with overdispersion model is adjusted for dosing regimen and
prior exacerbation status.
Omalizumab/placebo.
§Poisson regression with overdispersion model including terms for treatment, dosing
regimen, and prior exacerbation status.
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High eosinophil count: A potential biomarker
for assessing successful omalizumab treat-
ment effects
To the Editor:
Some patients with atopic asthma have ongoing symptoms and
exacerbations despite normal lung function.1 Poor asthma con-
trol, or an exacerbation, often results in the need for intervention
with oral corticosteroids.2 Many factors contribute to the loss of
control including allergen exposure and/or a respiratory infec-
tion.3 Because IgE plays an important role in asthma, treatment
to reduce serum IgE, and hence tissue-bound IgE, has been shown
to modify the response to inhaled allergen and exacerbations.4,5
Omalizumab (Xolair; Genentech Inc, South San Francisco,
Calif), an injectable recombinant humanizedmAb that selectively
binds to free IgE, is currently indicated in the United States for the
treatment of patients (aged >_12 years) withmoderate-to-severe al-
lergic asthmawho remain inadequately controlled on inhaled cor-
ticosteroids (ICS).6
Here we report the findings of a 24-week, multicenter, parallel-
group, double-blind, randomized, placebo-controlled trial con-
ducted to fulfill a postmarketing commitment that evaluated the
effectiveness of omalizumab in patients aged 12 to 75 years with
atopic asthma (elevated serum total IgE levels >_30-<_1300 IU/mL)
who remained symptomatic and uncontrolled on ICS with or
without other controller medications despite having normal lung
function (baseline predicted FEV1 >_80%). The primary end point
was the average rate of asthma exacerbations, predefined in the
study protocol as a worsening of asthma requiring treatment
with oral or intravenous corticosteroids and/or a doubling of the
baseline ICS dose for 3 or more days during the treatment period.
Further details of study methodology, including secondary and
preplanned analyses, are detailed in this article’s Online Reposi-
tory at www.jacionline.org. To investigatewhat factors might pre-
dict treatment outcomes in this patient population, a preplanned
analysis was performed in 2 subgroups divided according to eo-
sinophil counts at screening: low (<300/mL) and high (>_300/mL).
Overall, 328 randomized patients received at least 1 dose of
study treatment and were evaluable for efficacy and safety
(omalizumab [n 5 157] or placebo [n 5 171]; see Fig E1 in
this article’s Online Repository at www.jacionline.org). Patient
demographics and baseline characteristics werewell balanced be-
tween the 2 treatment groups, as well as in the subgroups with
high (>_300/mL) or low (<300/mL) eosinophil counts at baseline
(see Tables E1 and E2 in this article’s Online Repository at
www.jacionline.org).
The primary end point of the study was not met. Although there
was a 27% reduction in protocol-defined exacerbation rates withomalizumab versus placebo (0.21 vs 0.26 per patient during the
24-week treatment period; relative risk [RR], 0.73; 95% CI,
0.44-1.24), this treatment effect was not statistically significant
(Table I). A sensitivity analysis showed that the rate of exacerba-
tions defined according to the recent American Thoracic Society
(ATS)/European Respiratory Society (ERS) update7 was reduced
by 14% (0.19 vs 0.20; RR, 0.86; 95%CI, 0.48-1.55). In addition, a
subgroup analysis demonstrated that there was no information
contributed by patients with no prior exacerbations. Because of
the fact that patient eligibility for enrollment was highly limited,
the study was underpowered to demonstrate a statistically signif-
icant treatment effect in the primary end point. As the primary ef-
ficacy end point did not reach statistical significance, the
improvements in lung function (secondary efficacy end points)
observed with omalizumab were not considered statistically sig-
nificant because of the prespecified gatekeeping strategy used to
control the familywise type I error rate (see Figs E2-E4 and
Table E3 this article’s Online Repository at www.jacionline.org
FIG 1. Rate ratio (95% CI) of protocol-defined asthma exacerbation by subgroup.
J ALLERGY CLIN IMMUNOL
AUGUST 2013
486 LETTERS TO THE EDITORfor results of secondary end points/preplanned analyses). Simi-
larly, results for the following subgroup analysis should be inter-
preted with caution.
It is clinically noteworthy that the treatment response to
omalizumab appeared to differ according to patients’ blood
eosinophil count at baseline. In patients with an eosinophil count
of 300/mL or more, omalizumab treatment resulted in a 59%
reduction in the rate of protocol-defined exacerbations versus
placebo (0.25 vs 0.59; RR, 0.41; 95% CI, 0.20-0.82; Fig 1). In the
corresponding sensitivity analysis according to the ATS/ERS ex-
acerbation definition, the omalizumab group exhibited a 45% re-
duction compared with placebo (0.22 vs 0.40 per patient; RR,
0.55; 95% CI, 0.25-1.22). In patients with low eosinophil counts
at baseline, omalizumab showed no improvement versus placebo
in the protocol-defined exacerbation rate (0.17 vs 0.16; RR, 1.07;
95% CI, 0.45-2.53) (Table I).
Although the primary end point was not achieved in this study,
the markedly improved effectiveness of omalizumab in terms of
the reduction in the rate of exacerbations in the subgroupwith high
eosinophil count is a potentially important finding. Although the
treatment effect was reduced when the ATS/ERS exacerbation
definition was used, there remained a trend toward a lower
exacerbation rate in omalizumab-treated patients with high eosin-
ophil counts compared with placebo. Furthermore, patients in the
placebo group with eosinophil counts of 300/mL or more had a
higher exacerbation rate comparedwith those in the loweosinophil
subgroup, suggesting that high eosinophil counts may be a
prognostic indicator for patients at greater risk of exacerbations.
Our subgroup analyses therefore indicate that eosinophil count
may have value as a biomarker to identify patients with symp-
tomatic asthma despite normal lung function who could poten-
tially benefit from omalizumab treatment. The peripheral blood
eosinophil count is a well-recognized marker of inflammation in
asthma,8 and previous studies have demonstrated a consistent pat-
tern of improved clinical outcomes associated with decreased
eosinophil counts in patients receiving omalizumab.9 Eosinophil
count is recommended as a supplemental biomarker measure by
the Asthma Outcomes workshop.10
Omalizumab was well tolerated in the present study, and safety
data were consistent with the established profile of omalizumab,
with no new safety signals observed. Details of the safety findings
are included in Table E4 the Online Repository at www.
jacionline.org.
In summary, our findings suggest that the small subpopulation
of patients with normal lung function but ongoing symptoms,
despite treatment with ICS, who have high peripheral blood
eosinophils may benefit from treatment with omalizumab.Although the present study is limited by the lack of statistical
significance for the primary end point, the subgroup analyses
indicate that eosinophil count may have potential as a biomarker
to predict omalizumab treatment outcomes, and should be further
investigated in randomized, double-blind, placebo-controlled
trials.
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METHODS
Patients
To be eligible for inclusion, patients were required to have inadequate
symptom control, defined as a daytime asthma symptom score of 1 or more on
at least 20 days and a mean symptom score of 1.5 or more, or nighttime
awakening due to asthma symptoms more than 4 times during the 4-week run-
in period.
Patients were excluded if they had received chronic systemic corticoste-
roids (oral or intravenous) within 3 months or had received a burst of oral
corticosteroids within 2 weeks prior to screening; had received omalizumab
therapy at any time within 12 months prior to screening; had a significant
medical illness/active lung disease other than asthma; were pregnant/lactat-
ing; or had taken immunosuppressants or other investigational drugs within
the 30 days prior to screening.
To increase the rate of enrollment, the study protocol was amended to
remove the inclusion criterion requiring that patients had to have had at least
1 exacerbation requiring corticosteroids/a doubling of the dose of ICS.
Study design
After a 4-week run-in period, eligible patients were randomized to receive
omalizumab or placebo in a 1:1 ratio for 24 weeks, stratified by study center
and dosing regimen (every 2 or 4 weeks). Omalizumab dose was determined
on the basis of pretreatment serum total IgE level (IU/mL) and body weight
(kg) according to the European omalizumab dosing table, which ensured a
minimum omalizumab dose of 0.008 mg/kg/IgE (IU/mL) every 2 weeks or a
minimum of 0.016mg/kg/IgE (IU/mL) every 4 weeks. Nomodifications to the
doses of omalizumab or concomitant asthma/nonasthma medications (estab-
lished prior to the 4-week run-in period) were allowed during the study.
The study was conducted according to US Food and Drug Administration
regulations, the International Conference on Harmonisation E6 Guideline for
Good Clinical Practice, and any national requirements, and was approved by
local or central institutional review boards. Written informed consent was
obtained from all patients (or the patients’ parent/legal guardian if the patients
were younger than 18 years) prior to enrollment.
Randomization and blinding. A permuted block design of
randomization was used to ensure treatment balance overall, within each study
center, and within the study drug dosing regimens (subcutaneous administra-
tion every 2 or 4 weeks). A list of randomization numbers in 10 blocks of 4 was
generated for each study center and each of the 2 study drug dosing regimens.
A randomization schedule was generated for all sites as an ASCII file by
including the following information: randomization number, treatment
assignment, site, and dosing frequency. All patients, investigators, site person-
nel, and the study sponsor were blinded to the treatment assignment throughout
the study. Study drug supplies were shipped blinded to treatment assignment to
each site. Because of differences in viscosity between the omalizumab and
placebo preparations, which may have compromised blinding, the drug was
reconstituted and/or administered by an unblinded pharmacist or other
designated individual who was not involved in recording study data.
Assessments and variables
The primary efficacy outcomewas the average rate of asthma exacerbations
during the 24-week treatment period, which started from the first dosing date
and ended 30 days following the last dosing date/date of study completion or
early discontinuation, whichever was earlier. The definition of asthma
exacerbations used in this study predates that specified by a recent ATS/
ERS workshop.E1 A sensitivity analysis was conducted to evaluate the effect
of omalizumab on ATS/ERS-defined exacerbations, which excluded doubling
of the patient’s baseline ICS dose from the protocol definition of an
exacerbation.
Secondary outcomemeasures included change from baseline to week 24 in
nocturnal and daytime asthma symptom scores (mean symptom score
recorded daily on a 0-4 scale during the last 28 days), and relative change
from baseline to week 24 in % predicted FEV1. Patients monitored their
asthma symptoms, peak expiratory flow rate, and rescue medication use by
using case report forms provided by the study sponsor, which were completed
twice-daily during the 4-week run-in period and the treatment period. All spi-
rometry measurements were performed in accordance with ATS guidelines.E2
Safety was evaluated by recording and monitoring the frequency and
severity of adverse events (AEs), with particular attention given to AEs of
special interest (including malignancies, urticaria, hypersensitivity reaction,
injection-site reaction, bleeding-related events, and arterial thromboembolic
event). The frequency of serious AEs (including deaths) was also recorded,
and clinical laboratory evaluations were conducted.
Statistical analysis
Efficacy analyses were performed on all randomized patients who received
at least 1 dose of the study drug, defined as the modified intent-to-treat (mITT)
population. All patients received their treatment of assignment; consequently,
the mITT population in this study was identical to the safety-evaluable
population used for the safety analyses.
Poisson regression model adjusted for overdispersion was used to analyze
the primary efficacy end point to assess the effect of omalizumab on the rate of
protocol-defined asthma exacerbations. A nonparametric comparison between
treatment groups was performed by using the rank-based van Elteren test with
standardized midrank (modified ridit) weights.
Analysis of all primary and secondary efficacy end points was adjusted for
2 covariates: dosing schedule (every 2 or 4 weeks) and prior exacerbation
status. The common RR was estimated across strata, and the corresponding
95% CI was calculated.
Percentage predicted FEV1 values were calculated on the basis of the
method of Crapo et alE3 for patients 18 years or older and the method of Polgar
and PromadhatE4 for patients younger than 18 years. Absolute change from
baseline toweek 24was compared between treatment groups by using an anal-
ysis of covariance (ANCOVA) model in which the baseline % predicted FEV1
value, dosing regimen, and asthma exacerbation status (during the 12 months
prior to screening or during the run-in period) were covariates. Relative
change from baseline to week 24 was compared between treatment groups
by using an ANOVA model. The last-observation-carried-foward (LOCF)
method was used for imputation of missing data for patients who discontinued
prematurely.
Change from baseline to week 24 in nocturnal and daytime asthma
symptom scores was compared between treatment groups by using an
ANCOVA model with covariates including baseline symptom scores, dosing
regimen, and asthma exacerbation status. When symptom scores were
unavailable for more than 7 days out of the 28 days prior to a given visit,
the mean symptom scores were considered missing for the visit and were
imputed by using the LOCF method.
In the context of multiple hypothesis testing, the familywise type I error
was controlled through a gatekeeping strategy with the end points in the
following statistical hierarchy: the primary end point of average rate of
protocol-defined asthma exacerbations during the 24-week treatment period,
followed, in order, by the secondary end points of changes at week 24 from
baseline in % predicted FEV1, changes in nocturnal symptoms score, and
changes in daytime symptoms score. If a lack of statistical significance was
identified at any level, then testing could not continue beyond that level.
A preplanned subgroup analysis was conducted to evaluate the effect on
eosinophil counts at screening, with patients divided into 2 groups: low (<300/
mL) and high (>_300/mL). This analysis was planned prior to unblinding of the
study data in response to accumulating evidence about the importance of
eosinophil counts in atopic asthma. However, eosinophil counts were not
necessarily collected for all patients at baseline and may therefore have been
missing at random depending on their availability in the original laboratory
test records. Preplanned subgroup analyses were also conducted to evaluate
the effect of study drug dosing regimen (2 weeks vs 4 weeks) and prior
exacerbation status (yes/no; during the 12 months prior to screening or during
the run-in period).
As this study was designed to fulfill a postmarketing commitment to study
omalizumab in a population that was not consistent with that for which
treatment is indicated in clinical practice, the number of patients eligible for
enrollment was highly limited. According to current Global Initiative for
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Asthma (GINA) guidelines on asthma management, omalizumab is recom-
mended as an add-on treatment to a medium- or high-dose ICS plus
long-acting b2-agonist following failure of a leukotriene modifier or
sustained-release theophylline.E5 At the end of the 4-year recruiting period,
approximately 330 patients had been enrolled. Under a Poisson regression
model, 330 patients provided approximately only 30% power to demonstrate
a statistically significant treatment effect for the 27% reduction in the asthma
exacerbation rate observed in this study.
RESULTS
The study was conducted at 81 centers in the United States, and
patient disposition is shown in Fig E1. The study was completed
by 289 (86.8%) patients (84.9% of the omalizumab group; 88.5%
of the placebo group). Overall, 328 patients received at least
1 dose of study treatment (mITT population); 2 patients in the
omalizumab group and 3 in the placebo group were randomized
but did not receive treatment as they were found to be ineligible
after randomization.
Patient demographics and baseline characteristics were well
balanced between the treatment groups (Tables E1 and E2). The
majority of patients (79.3%) received concomitant ICS and
long-acting b2-agonist, which included 4.9% receiving a third
controller. During the 12 months prior to randomization and dur-
ing the run-in period, 38.7% of the patients had no exacerbations,
48.8% had 1 asthma exacerbation, and 12.5% had 2 or more
exacerbations.
Secondary efficacy analyses
One omalizumab-treated patient had a low baseline FEV1 value
of 0.95 L, resulting in relative changes of more than 200% in
FEV1 at subsequent visits. The spirometry data from this patient
were considered outliers, and were removed from the analysis.
Mean 6 SD FEV1 increased by 0.055 6 0.319 L from baseline
to week 24 in the omalizumab group, compared with a decrease
of 0.0266 0.338 L in the placebo group. Mean6 SD%predicted
FEV1 increased by 1.78 6 9.69 in the omalizumab group and
decreased by 0.986 10.2 in the placebo group. Based on the AN-
OVA model, the treatment effect in relative change of FEV1 was
estimated to be 3.5% (95% CI, 0.9-6.1) (Fig E2).
Change in mean 6 SD nocturnal asthma symptom scores at
week 24 from baseline was summarized as 20.48 6 0.77 in the
omalizumab group and 20.49 6 0.67 in the placebo group.
Change in mean 6 SD daytime asthma symptom scores was
summarized as 20.73 6 0.72 in the omalizumab group and
20.67 6 0.72 in the placebo group. Based on the ANCOVA
model, the treatment effects in change in nocturnal and daytime
asthma symptom scores were not statistically significant and
estimated to be 0.01 (95%CI,20.12 to 0.14) and20.05 (95%CI,
20.19 to 0.09), respectively.
Subgroup analyses
Data on the peripheral blood eosinophil counts at screening
were retrieved from 217 of 328 patients in the mITT population in
support of a prespecified analysis. Of note, 91 (41.9%) patients
had an eosinophil count of 300/mL or more at baseline.
In patients with a high eosinophil count at baseline, the least
squares mean treatment effect for relative change in FEV1 from
baseline to week 24 was estimated to be 7.35% (95% CI, 1.38-
13.31). In patients with a low baseline eosinophil count, the least
squares mean treatment effect for relative change in FEV1 was
3.67% (95% CI, 20.46 to 7. 81).
There were no significant differences in treatment effect
between treatment groups when patient data were analyzed
according to exacerbation history or dosing regimen (Fig E3). No-
tably, in patientswith andwithout a exacerbation history, protocol-
defined exacerbation rates per patient were 0.30 and 0.04 in the
omalizumab group and 0.40 and 0.06 in the placebo group, respec-
tively, during the 24-week treatment period. Indeed, this subgroup
analysis demonstrated that there was no information contributed
by patients with no prior exacerbations (Table E3).
No correlation was found between baseline IgE levels and
eosinophil counts at screening (data not shown).
Sensitivity analyses
Exacerbations according to the ATS definition. The
ATS definition specifies that in clinical trials a severe asthma
exacerbation should include at least 1 of the following: (1) use of
systemic corticosteroids or an increase from a stable maintenance
dose, for at least 3 days; or (2) hospitalization or emergency room
visit because of asthma, and requiring systemic corticosteroids.
Moderate exacerbations are defined as events that are troublesome
to the patient, and that prompt a need for a change in treatment, but
that are not severe. These events are clinically identified by being
outside the patient’s usual range of day-to-day asthma variation.E6
Sensitivity analyses were conducted to explore the effect of
omalizumab on exacerbations defined according to these ATS
definitions (ie, excluding doubling of ICS from the definition).
FEV1 data. For the total study population, including a patient
with outlying values, mean percentage predicted FEV1 increased
by 3.8% in the omalizumab group and decreased by 1.0% in the
placebo group from baseline to week 24. Mean FEV1 increased
by 0.064 L from baseline to week 24 in the omalizumab group,
compared with a decrease of 0.027 L in the placebo group. Based
on the ANOVA model, the treatment effect in relative change
from baseline in FEV1 at week 24 was estimated to be 4.8%
(95% CI, 1.2-8.4) (Fig E4).
Safety
The overall incidence of AEs reported with omalizumab was
similar to that of the placebo group; most AEs were mild or
moderate in severity, and serious AEs were uncommon (Table
E4). Four patients (1.2%) discontinued the study because of an
AE: 3 patients in the omalizumab group and 1 patient in the pla-
cebo group. In the omalizumab group, 1 patient each reported a
serious AE (arterial thromboembolic event and breast cancer),
neither of which was considered to be related to the study drug;
1 patient reported AEs of pollakiuria and micturition urgency
that were considered to be related to the study drug. The patient
in the placebo group reported a serious AE of diffuse large
B-cell lymphoma. No deaths were observed during the treatment
or follow-up periods.
No clinically relevant laboratory findings, including platelet
count results, were reported. The incidence of treatment-emergent
AEs of special interest (malignancies, urticaria, hypersensitivity
reaction, injection-site reaction, bleeding-related events, and
arterial thromboembolic event) was low and similar between
treatment groups.NoAEsqualified as anaphylaxis, serumsickness
syndrome, Churg-Strauss syndrome, or parasitic infections.
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FIG E1. Patient disposition. *Five patients were found to be ineligible after enrollment.
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FIG E2. Least squaresmeans of relative change from baseline in FEV1 (mITT population [excluding 1 patient
with outlying spirometry data]). LSM, Least squares means (adjusted for dosing regimen and prior exacer-
bation status). *P 5 .04; P 5 .002; P 5 .02; **P 5 .008.
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FIG E3. Rate ratio (95% CI) of protocol-defined asthma exacerbation by prior exacerbation status and dosing
regimen subgroups. Q2, every 2 wk; Q4, every 4 wk.
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FIG E4. Least squares means of relative change from baseline in FEV1 (mITT population). LSM, Least
squares means (adjusted for dosing regimen and prior exacerbation status). *P 5 .02; P 5 .001;
P 5 .01; **P 5 .009.
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TABLE E1. Patient demographics and baseline characteristics
(mITT population)
Omalizumab
(n 5 157)
Placebo
(n 5 171)
Age (y), n (%)
12-17 25 (25.9) 20 (11.7)
18-64 127 (80.9) 143 (83.6)
>_65 5 (3.2) 8 (4.7)
Age, mean 6 SD (y) 36.0 6 14.7 38.1 6 15.1
Sex, n (%)
Male 47 (29.9) 55 (32.2)
Female 110 (70.1) 116 (67.8)
Race, n (%)
White 113 (72) 118 (69)
Black or African American 37 (23.6) 42 (24.6)
Asian 5 (3.2) 4 (2.3)
American Indian/Alaska Native 1 (0.6) 3 (1.8)
Other 1 (0.6) 4 (2.3)
Body weight (kg), mean 6 SD 77.9 6 21.6 83.2 6 21.9
Total serum IgE (IU/mL), mean 6 SD 196.3 6 160.2 199.7 6 168.3*
Prebronchodilator FEV1 (L), mean 6 SD 2.8 6 0.7 2.8 6 0.7
Prebronchodilator FEV1 (% predicted),
mean 6 SD
85.7 6 13.4 85.9 6 11.4*
Prior exacerbations
0 58 (36.9) 69 (40.4)
1 80 (51.0) 80 (46.8)
2 13 (8.3) 19 (11.1)
>_3 6 (3.8) 3 (1.8)
Concomitant asthma medications, n (%)
ICS alone 30 (19.1) 33 (19.3)
ICS 1 LABA 124 (79.0) 136 (79.5)
ICS 1 LABA 1 other controllers 7 (4.5) 9 (5.3)
ICS dose (mg), mean 6 SD 488.7 6 258.8 527.7 6 271.1*
Puffs of rescue medication, mean 6 SD
Morning 1.2 6 1.0 1.2 6 1.1*
Evening 1.6 6 1.2 1.7 6 1.5§
Asthma symptom score, mean 6 SD
Nocturnal 1.1 6 0.9 1.0 6 0.8*
Daytime 1.5 6 0.7 1.5 6 0.7*
Eosinophil counts (L)
<300/mL 56 (52.3)k 70 (63.6){
>_300/mL 51 (47.7)k 40 (36.4){
LABA, Long-acting b2-agonist.
*n 5 170.
Exacerbations during the 12 mo prior to screening and during the run-in period.
The category ‘‘ICS 1 LABA’’ includes patients in the category ‘‘ICS 1 LABA 1
other controllers.’’
§n 5 169.
kn 5 107.
{n 5 110.
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TABLE E2. Patient demographics and baseline characteristics for the subgroups of patients with high or low eosinophil counts
High eosinophil subgroup (>_300/L) Low eosinophil subgroup (<300/L)
Omalizumab (n 5 51) Placebo (n 5 40) Omalizumab (n 5 56) Placebo (n 5 76)
Age (y), n (%)
12-17 11 (21.6) 7 (17.5) 7 (12.5) 7 (10.0)
18-64 38 (74.5) 32 (80.0) 48 (85.7) 61 (87.1)
>_65 2 (3.9) 1 (2.5) 1 (1.8) 2 (2.9)
Age (y), mean 6 SD 34.2 6 15.8 35.2 6 15.4 36.1 6 13.1 38.1 6 14.5
Sex, n (%)
Male 18 (35.3) 9 (22.5) 12 (21.4) 25 (35.7)
Female 33 (64.7) 31 (77.5) 44 (78.6) 45 (64.3)
Race, n (%)
White 41 (8.04) 28 (70.0) 39 (69.6) 50 (71.4)
Black or African American 7 (13.7) 8 (20.0) 14 (25.0) 16 (22.9)
Asian 2 (3.9) 2 (5.0) 3 (5.4) 2 (2.9)
American Indian/Alaska Native 0 1 (2.5) 0 0
Other 1 (2.0) 1 (2.5) 0 2 (2.9)
Body weight (kg), mean 6 SD 79.0 6 19.0 81.8 6 23.7 75.7 6 20.1 85.9 6 22.8
Total serum IgE (IU/mL), mean 6 SD 184.8 6 117.2 239.6 6 158.7* 176.1 6 147.8 149.9 6 136.6
Prebronchodilator FEV1 (L), mean 6 SD 2.8 6 0.8 2.7 6 0.6 2.7 6 0.5 2.9 6 0.7
Prebronchodilator FEV1 (% predicted), mean 6 SD 83.9 6 12.3 83.5 6 11.0 86.6 6 11.9 86.3 6 11.1
Prior exacerbations
0 14 (27.5) 9 (22.5) 20 (35.7) 28 (40.0)
1 28 (54.9) 24 (60.0) 31 (55.4) 33 (47.1)
2 8 (15.7) 6 (15.0) 1 (1.8) 9 (12.9)
>_3 1 (2.0) 1 (2.5) 4 (7.1) 0
Concomitant asthma medications, n (%)
ICS alone 10 (19.6) 8 (20.0) 14 (25.0) 13 (18.6)
ICS 1 LABA 40 (78.4) 32 (80.0) 41 (73.2) 57 (81.4)
ICS 1 LABA 1 other controllers 5 (9.8) 1 (2.5) 1 (1.8) 6 (8.6)
ICS dose (mg), mean 6 SD 516.1 6 262.8 528.5 6 283.1 492.8 6 307.4 568.4 6 283.0
Puffs of rescue medication, mean 6 SD
Morning 1.3 6 1.2 1.2 6 1.1 1.2 6 1.0 1.2 6 1.1
Evening 1.8 6 1.2 1.7 6 1.8 1.5 6 1.3 1.7 6 1.2
Asthma symptom score, mean 6 SD
Nocturnal 0.9 6 0.9 1.1 6 0.8 1.0 6 0.8 1.0 6 0.8
Daytime 1.6 6 0.6 1.5 6 0.9 1.5 6 0.7 1.5 6 0.6
LABA, Long-acting b2-agonist.
*n 5 39.
Exacerbations during the 12 mo prior to screening and during the run-in period.
The category ‘‘ICS 1 LABA’’ includes patients in the category ‘‘ICS 1 LABA 1 other controllers.’’
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TABLE E3. Change in protocol-defined asthma exacerbation rate
over the 24-week treatment period by status of having prior
exacerbations (mITT population)
Having prior exacerbations Omalizumab Placebo
Yes n 5 99 n 5 102
No. of protocol-defined asthma
exacerbations, n (%)
0 77 (77.8) 73 (71.6)
1 19 (19.2) 21 (20.6)
>_2 3 (3.0) 8 (7.8)
Unadjusted exacerbation rate* 0.30 0.40
Poisson regression
Ratio of exacerbation rates (95% CI) 0.74 (0.42-1.31)
P value .3026
No n 5 58 n 5 69
No. of protocol-defined asthma
exacerbations, n (%)
0 56 (96.6) 65 (94.2)
1 2 (3.4) 4 (5.8)
>_2 0 (0.0) 0 (0.0)
Unadjusted exacerbation rate* 0.04 0.06
Poisson regression
Ratio of exacerbation rates (95% CI) 0.65 (0.11-3.97)
P value .6407
*Number of protocol-defined asthma exacerbations/total patient-treatment period.
Poisson regression with overdispersion model is adjusted for dosing regimen.
Omalizumab/placebo.
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TABLE E4. Number (%) of patients with AEs (safety-evaluable
population)
Omalizumab
(n 5 157)
Placebo
(n 5 171)
Any AE 92 (58.6) 108 (63.2)
Serious AE 4 (2.5) 6 (3.5)
AEs with incidence >3% in any treatment
group*
Upper respiratory tract infection 15 (9.6) 17 (9.9)
Sinusitis 11 (7.0) 16 (9.4)
Nasopharyngitis 9 (5.7) 16 (9.4)
Influenza 7 (4.5) 1 (0.6)
Headache 7 (4.5) 10 (5.8)
Cough 7 (4.5) 5 (2.9)
Asthma 5 (3.2) 5 (2.9)
Pharyngitis 4 (2.5) 6 (3.5)
Back pain 3 (1.9) 6 (3.5)
Allergic rhinitis 3 (1.9) 7 (4.1)
Arthralgia 2 (1.3) 6 (3.5)
AEs of special interest
Malignancies 1 (0.6) 1 (0.6)
Urticaria 3 (1.9) 3 (1.8)
Hypersensitivity reaction 2 (1.3) 4 (2.3)
Injection-site reaction 2 (1.3) 1 (0.6)
Bleeding-related events 4 (2.5) 3 (1.8)
Arterial thromboembolic event 1 (0.6) 0
*MedDRA system organ class preferred term; ranked by frequency in the omalizumab
group.
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